Overview
Thymogen is a synthetic dipeptide consisting of glutamic acid and tryptophan, commonly abbreviated Glu-Trp and also known as oglufanide. It was developed within the Russian thymic peptide research tradition as a small immune bioregulator. Unlike many less-defined bioregulator complexes, Thymogen is a defined molecule, though the batch source lists molecular mass 349.34 g/mol and formula C16H19N3O6. It is not FDA-approved in the United States, but PubChem and drug-development databases describe investigational and non-US use histories.
The proposed mechanism centers on immune normalization rather than broad immune stimulation. Thymogen has been studied for effects on T-cell function, cytokine signaling, inflammatory responses, and hematopoietic regulation. In vitro work with Khavinson peptides found changes in inflammatory cytokine patterns in THP-1 monocyte/macrophage models, while broader literature describes short peptides as possible regulators of gene expression. The practical interpretation is immunomodulatory potential with incomplete Western clinical validation.
Clinical enthusiasm should be balanced with regulatory reality. Thymogen is not FDA-approved for immune deficiency, viral infection, cancer, chronic fatigue, autoimmunity, vaccine enhancement, or anti-aging. Some historical studies and non-US clinical use may be relevant, but product quality, route, indication, and endpoints vary. People with autoimmune disease, cancer, organ transplants, immunosuppressive therapy, or recurrent infections should not self-manage immune issues with peptide products.
This guide focuses on Thymogen's structure, plausible immune mechanisms, unknowns in pharmacokinetics, safety concerns, and realistic use boundaries. For peptide users, Thymogen is more defined than many tissue complexes, but it still demands caution. Immune effects can be subtle, context-dependent, and sometimes unwanted, so objective medical context matters more than generalized claims about immune support.
Quick facts
- Mechanism
- Defined Glu-Trp dipeptide with immunomodulatory activity
- Primary use
- Immune bioregulation research
- Evidence
- moderate
- FDA
- Not approved
- Route
- Intranasal, oral, or injectable depending on formulation and country
- Typical results
- Immune-marker effects studied over days to weeks
Chemical information
Thymogen is a synthetic Glu-Trp dipeptide, also listed in databases under oglufanide and glutamyltryptophan. The batch source lists molecular mass 349.34 g/mol and formula C16H19N3O6, while public chemistry databases may list related salt or parent structures differently.
How Thymogen works
Thymogen is proposed to modulate immune function through short-peptide effects on lymphocyte and monocyte/macrophage signaling. The Glu-Trp sequence may influence cytokine output, cell proliferation patterns, and gene-expression programs involved in immune homeostasis. It is best understood as an immunomodulatory peptide rather than a simple immune stimulant. Human evidence exists but is heterogeneous, and US regulatory approval has not been granted.
Thymic peptides are historically linked to T-cell maturation and immune coordination. Thymogen was developed as a minimal synthetic dipeptide derived from that research direction. In cell models, related Khavinson peptides have been reported to reduce LPS-stimulated inflammatory cytokines and influence proliferative signaling. These findings support a plausible immune-regulatory effect, but they do not define a universal clinical indication.
The broader short-peptide literature proposes that peptides can interact with DNA, chromatin, and transporter systems. For Thymogen, the presence of tryptophan may also matter for immune-cell metabolism because activated immune cells depend on amino acid transport and tryptophan-related pathways. These mechanistic threads are biologically plausible, but clinical response likely depends on baseline immune state, route, dose, and disease context.
Oglufanide has appeared in investigational development for conditions such as chronic hepatitis C and oncology-related immune modulation. That history suggests more than supplement-level interest, but it also highlights that investigational status is not approval. Without modern, indication-specific, replicated trials, Thymogen should be approached as a research immunomodulator rather than a validated treatment for infections or immune disorders.
- Defined dipeptide: Glu-Trp sequence gives Thymogen clearer identity than complex extracts
- Immune modulation: Proposed to normalize T-cell and monocyte/macrophage signaling
- Cytokine effects: In vitro data support effects on inflammatory mediator patterns
- Gene-regulation model: Fits broader short-peptide hypotheses around transcriptional regulation
- Not FDA-approved: No US-approved indication exists despite non-US and investigational history
- Context dependent: Immune effects may differ in infection, autoimmunity, cancer, and immunosuppression
Pharmacokinetics
Published human pharmacokinetic details are limited and route-dependent. Intranasal, oral, and injectable formulations should not be assumed interchangeable, and no FDA label defines a US dosing or PK framework.
| Parameter | Value | Significance |
|---|---|---|
| Molecular type | Synthetic dipeptide | More defined than tissue peptide complexes |
| Routes studied/used | Intranasal, oral, injectable | Exposure may differ substantially by formulation |
| Half-life | Not well established in public human data | Avoid assuming a precise duration |
| Bioavailability | Route-dependent; not fully characterized | Clinical effects cannot be inferred from dose alone |
| Primary monitoring | Clinical context and immune markers when indicated | Immune symptoms alone are nonspecific |
| Metabolism | Likely peptide hydrolysis | Expected breakdown into amino acid components or fragments |
Dosing & administration
There is no FDA-approved Thymogen dosing in the United States. Non-US products and investigational protocols have used different routes and schedules, so users should not mix instructions between intranasal, oral, and injectable forms.
Immune-focused research should start with a clear reason for use, baseline health context, medication review, infection history, autoimmune history, and relevant labs only when clinically meaningful. More immune activity is not always better.
People with autoimmune disease, cancer, organ transplant, chronic infections, unexplained fevers, low white blood cell counts, or immunosuppressive therapy should involve a clinician before considering any immune-active peptide.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Thymogen appears more defined than many bioregulator complexes, but immune modulation can be risky in the wrong context. Lack of FDA approval and route-dependent product variability remain major practical concerns.
Common
- • Nasal irritation with intranasal products
- • Mild headache
- • Fatigue
- • Transient nausea
- • Injection-site irritation if injected
- • Mild flu-like symptoms
Serious / potential risks
- • Allergic reaction
- • Unpredictable effects in autoimmune disease
- • Potential concern in active malignancy or cancer therapy
- • Interaction uncertainty with immunosuppressive drugs
- • Contamination or sterility risk from unregulated injectable products
Drug interactions
Formal interaction data are limited; concerns are based on possible immune effects and route-specific formulation issues.
| Medication | Interaction | Recommendation |
|---|---|---|
| Immunosuppressants | May theoretically oppose intended immune suppression | Avoid unsupervised use |
| Cancer immunotherapy | Immune modulation could complicate toxicity or response assessment | Use only with oncology input |
| Corticosteroids | May blunt or confound immune effects | Review indication and timing with clinician |
| Vaccines | No proven vaccine-enhancing role | Do not use to replace standard vaccine guidance |
| Other immune peptides | Stacking increases unpredictability | Avoid multi-peptide immune stacks without monitoring |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Non-US intranasal or capsule products | $20-$100 per package | Regulatory status and authenticity vary |
| Research peptide suppliers | $30-$100+ per vial | Sterility and identity testing are important |
| Clinical monitoring | Variable | Needed when immune disease or immunosuppressive therapy is involved |
The bottom line
Thymogen is a defined Glu-Trp immunomodulatory dipeptide with more identifiable chemistry than many bioregulator complexes. It has plausible and published immune-related research, but it is not FDA-approved and should not be used as a casual immune booster or substitute for diagnosis and treatment.
Best for
- • Immune bioregulation research
- • Users needing a defined short peptide rather than a complex extract
- • Clinician-supervised exploratory immune protocols
- • Educational comparison with thymic peptides
Not for
- • Self-treating serious infection
- • Unsupervised autoimmune disease use
- • Cancer patients without oncology input
- • Replacing vaccines or antimicrobial therapy
Related compounds
Svetinorm
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Taxorest
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Tesamorelin
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Testagen
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] National Center for Biotechnology Information. PubChem Compound Summary for CID 100094, Thymogen. PubChem (2026).
- [2] Avolio F, Martinotti S, Khavinson VK, et al.. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences (2022). doi: 10.3390/ijms23073607
- [3] Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021). doi: 10.3390/molecules26227053 PMID: 34834147
- [4] Khavinson VKh, Linkova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bulletin of Experimental Biology and Medicine (2016). doi: 10.1007/s10517-016-3596-7 PMID: 27909961
- [5] Kozlov IG, Gromova OA, Torshin IY, et al.. The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples. Pharmaceuticals (2024). doi: 10.3390/ph17050603
- [6] Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences (2022). doi: 10.3390/ijms23147733